BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Grass Roots Research Initiates Coverage on Ingen Technologies, Inc. (IGTN) With a STRONG BUY Recommendation


12/3/2012 12:18:10 PM

SAN RAFAEL, CA--(Marketwire - December 03, 2012) - Grass Roots Research & Distribution Inc. (GRRD), Wall Street's leading independent micro-cap research firm, has announced that it has initiated coverage on Ingen Technologies Inc. (PINKSHEETS: IGNT) with a STRONG BUY recommendation and a 12-month price target of $.15 per share. GRRD provides an in-depth analysis, including 5-year financial and valuation projections, on Ingen's business and its significant growth drivers. A copy of the report is available at http://ingen-tech.com/files/documents/Ingen_Final_Report_11016012.pdf.

An excerpt from the report states, "IGNT common stock is valued at $0.15 per share, 2727% higher than the current market price of $0.0055 per share. The stock is an interesting short term trade and potentially a good long term investment."

About Grass Roots Research & Distribution Inc. (GRRD)

GRRD is Wall Street's leading independent micro-cap research firm, concentrating on emerging companies with strong management teams focused on shareholder value and sustainable competitive advantage. GRRD, led by renowned security analyst, Paul Cohen, this CFA analyst written research report highlight the company's market opportunity, technology, management, competition and other key differentiators that may affect their long- and short-term valuation. GRRD focuses on those public companies that lack or have minimal Wall Street research analyst coverage. GRRD research reports are commissioned and paid for by the companies covered, or by third parties. For more information, visit: www.grassrootsrd.com.

This report/release is for informational purposes only. All information contained herein is based on public information. GRRD complies with securities laws, regulations and ethical standards as related to our legal and compliance requirements. Certain securities regulations are cited and disclaimed in our Disclaimer. Ethical standards as related to our firm are the foundation of those securities laws and regulations we follow. Our firm is not a member of any association for other research providers. Our firm's policy is to comply with any new securities laws and regulations that might be promulgated in the future. GRRD is a not a registered investment advisor that distributes contracted third party independent research purchased from outside third party contracted securities analysts. To access the complete disclosure and disclaimer, download a copy of the Ingen Technologies Inc. report at www.grassrootsrd.com.

About Ingen Technologies:
Ingen Technologies, Inc. (PINKSHEETS: IGNT), through its wholly owned subsidiary, is an emerging medical device manufacturer that has developed and patented a proprietary medical technology for patients suffering with COPD (Chronic Obstructive Pulmonary Disease) such as chronic bronchitis, emphysema, and asthmatic bronchitis and who require oxygen therapy through home healthcare, hospitals, military and government-based medical facilities. The Company has delivered this product to a global customer base in the $4 billion respiratory market since 1998.

Safe Harbor Statement: The Private Securities Litigation Reform Act of 1995 provides a "Safe harbor" for forward-looking statements. Certain of the statements contained herein, which are not historical facts, are forward-looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.

For more information about Grass Roots Research & Distribution Inc. contact Paul Cohen at paul@cohenresearch.com or visit www.grassrootsrd.com and for more information on Ingen Technologies contact Gary Tilden, COO at gary@ingen-tech.com or go to www.ingen-tech.com.


Contact:
Gary Tilden
951-688-7840
www.ingen-tech.com
Email Contact


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->